Pharmaceutical Technology43m
FDA grants ODD to NMD Pharma’s Charcot-Marie-Tooth disease therapy
The US FDA has granted ODD to NMD Pharma’s oral lead development programme, NMD670, designed to treat Charcot-Marie-Tooth disease (CMT).
Pharmaceutical Technology2h
Ultragenyx’s Evkeeza secures EU approval for young children with rare cholesterol disorder
The decision follows a positive recommendation received from the Committee for Medicinal Products for Human Use (CHMP) in November 2024.
Pharmaceutical Technology2h
Amgen’s Imdylltra wins conditional MHRA licence for lung cancer
Amgen’s bispecific T-cell engager (BiTE) led to an ORR of 41% in patients with extensive-stage small cell lung cancer.
Pharmaceutical Technology3h
Heart failure market estimated to grow, driven by pipeline agents aimed at unmet needs
The heart failure market is expected to grow at a 9.6% CAGR from $13.5bn in 2022 to $33.7bn in 2032 in the 7MM.
Pharmaceutical Technology3h
Abu Dhabi Stem Cells Center develops clinical-grade iPSCs
The Abu Dhabi Stem Cells Center (ADSCC) has developed clinical-grade induced pluripotent stem cells (iPSCs) that meet GMP protocols.
Pharmaceutical Technology4h
China’s NMPA approves GSK’s Nucala for CRSwNP treatment
The China NMPA has approved GSK’s Nucala (mepolizumab) as an add-on treatment along with intranasal corticosteroids to treat CRSwNP.
Pharmaceutical Technology12h
MK-6837 by Merck for Solid Tumor: Likelihood of Approval
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...
Pharmaceutical Technology12h
CLN-619 by Cullinan Therapeutics for Relapsed Multiple Myeloma: Likelihood of Approval
CLN-619 is under clinical development by Cullinan Therapeutics and currently in Phase I for Relapsed Multiple Myeloma.
Pharmaceutical Technology12h
PF-07832837 by Pfizer for Asthma: Likelihood of Approval
PF-07832837 is under clinical development by Pfizer and currently in Phase I for Asthma. According to GlobalData, Phase I drugs for Asthma have a 74% phase transition success rate (PTSR) indication ...
Pharmaceutical Technology12h
Anti-CDH17 CAR-T Cells by UTC Therapeutics for Pancreatic Cancer: Likelihood of Approval
Anti-CDH17 CAR-T Cells is under clinical development by UTC Therapeutics and currently in Phase I for Pancreatic Cancer.
Pharmaceutical Technology12h
CD19-CD22 CAR-T cells by Shanghai Biomed-Union Biotechnology for Unspecified B-Cell Lymphomas: Likelihood of Approval
CD19-CD22 CAR-T cells is under clinical development by Shanghai Biomed-Union Biotechnology and currently in Phase II for Unspecified B-Cell Lymphomas.